CXCR4抑制剂普乐沙福联合硼替佐米作为化疗增敏策略治疗复发/难治性多发性骨髓瘤的I/II期试验
该I/II期试验评估普乐沙福联合硼替佐米在复发/难治性多发性骨髓瘤中的安全性、最大耐受剂量及疗效。共纳入58例患者,I期确定最大耐受剂量为普乐沙福0.32 mg/kg联合硼替佐米1.3 mg/m2,II期总缓解率48.5%,临床获益率60.6%,中位无病生存期12.6个月。
要点
- 普乐沙福联合硼替佐米的最大耐受剂量为普乐沙福0.32 mg/kg、硼替佐米1.3 mg/m2。
- II期总缓解率48.5%,临床获益率60.6%,中位无病生存期12.6个月。
- CyTOF分析显示普乐沙福可显著动员浆细胞、CD34+干细胞和免疫T细胞。
核心结论
- 普乐沙福联合硼替佐米在复发/难治性多发性骨髓瘤中安全,且客观缓解率较高。
研究设计与样本
- I/II期临床试验,共纳入58例既往接受1-5线治疗的多发性骨髓瘤患者,中位年龄63岁(范围43-85),78%既往接受过硼替佐米。
主要发现
- I期确定最大耐受剂量为普乐沙福0.32 mg/kg联合硼替佐米1.3 mg/m2。
- II期总缓解率为48.5%,临床获益率为60.6%,中位无病生存期为12.6个月。
- CyTOF分析显示普乐沙福可显著动员浆细胞、CD34+干细胞和免疫T细胞。
关键数值与推荐
- I期最大耐受剂量:普乐沙福0.32 mg/kg,硼替佐米1.3 mg/m2。
- II期总缓解率48.5%,临床获益率60.6%,中位无病生存期12.6个月。
临床怎么用
- 对于复发/难治性多发性骨髓瘤患者,可考虑普乐沙福联合硼替佐米作为化疗增敏策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We tested the hypothesis that using CXCR4 inhibition to target the interaction between the tumor cells and the microenvironment leads to sensitization of the tumor cells to apoptosis. Eligibility criteria included multiple myeloma (MM) patients with 1-5 prior lines of therapy. The purposes of the phase I study were to evaluate the safety and maximal-tolerated dose (MTD) of the combination. The treatment-related adverse events and response rate of the combination were assessed in the phase II study. A total of 58 patients were enrolled in the study. The median age of the patients was 63 years (range, 43-85), and 78% of them received prior bortezomib. In the phase I study, the MTD was plerixafor 0.32 mg/kg, and bortezomib 1.3 mg/m2 . The overall response rate for the phase II study was 48.5%, and the clinical benefit rate 60.6%. The median disease-free survival was 12.6 months. The CyTOF analysis demonstrated significant mobilization of plasma cells, CD34+ stem cells, and immune T cells in response to plerixafor. This is an unprecedented study that examines therapeutic targeting of the bone marrow microenvironment and its interaction with the tumor clone to overcome resistance to therapy. Our results indicate that this novel combination is safe and that the objective response rate is high even in patients with relapsed/refractory MM. ClinicalTrials.gov, NCT00903968.
引用
- Ghobrial IM, Liu CJ, Zavidij O, et al. Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. Am J Hematol. 2019. PMID: 31456261. doi:10.1002/ajh.25627
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。